Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
REGN
$796.55
$-4.46
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Next Earnings
2026-01-11
Beta
0.389
Average Volume
992903
Market Cap
82269530403
Last Dividend
3.52
CIK
0000872589
ISIN
US75886F1075
CUSIP
75886F107
CEO
Leonard S. Schleifer
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
15158
IPO Date
1991-04-02
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Hennion & Walsh Asset Management Inc. Sells 1,206 Shares of Regeneron Pharmaceuticals, Inc. $REGN | Hennion and Walsh Asset Management Inc. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 53.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,047 shares of the biopharmaceutical company's stock after selling 1,206 shares during the period. Hennion and | Defense World | 2026-01-11 05:34:41 |
| Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Cerity Partners LLC | Cerity Partners LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 48.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 20,534 shares of the biopharmaceutical company's stock after acquiring an additional 6,676 shares during the period. Cerity Partners LLC's holdings in Regeneron | Defense World | 2026-01-11 03:24:44 |
| Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock? | Regeneron (REGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). | Zacks Investment Research | 2026-01-09 13:00:56 |
| Regeneron Pharmaceuticals, Inc. $REGN Stake Lifted by Clear Harbor Asset Management LLC | Clear Harbor Asset Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 26.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,637 shares of the biopharmaceutical company's stock after purchasing | Defense World | 2026-01-09 04:32:59 |
| Regeneron Just Moved From Underperform To Buy - Here's Why | Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) after a surprising shift in analyst sentiment? | Benzinga | 2026-01-07 16:18:11 |
| Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalysts | Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been upgraded by Bank of America, which raised its rating on the biotechnology company to ‘Buy' from ‘Underperform' and increased its price objective to $860 from $627, citing improving fundamentals across key products and multiple potential catalysts in 2026. Shares of Regeneron traded up 3.5% at about $803 on Wednesday afternoon. | Proactive Investors | 2026-01-07 14:17:08 |
| Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? | Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. | Zacks Investment Research | 2026-01-07 13:10:32 |
| REGN vs. ILMN: Which Stock Is the Better Value Option? | Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now? | Zacks Investment Research | 2026-01-07 12:41:16 |
| M2i Global, Volato Group partner with Titanium X on US critical minerals development | M2i Global Inc (OTC:MTWO), along with Volato Group which is in the process of merging with the company, announced a strategic collaboration with Titanium X... | Proactive Investors - Finance | 2026-01-07 09:33:00 |
| Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalysts | Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been upgraded by Bank of America, which raised its rating on the biotechnology company to ‘Buy’ from... | Proactive Investors - Finance | 2026-01-07 09:12:00 |
| ReconAfrica upsizes financing to fast-track Kavango, Angola and Gabon programs | Reconnaissance Energy Africa Ltd (TSX-V:RECO, OTCQX:RECAF) has upsized its earlier private placement annoucement of C$20M to C$32M to fund a broad 2026... | Proactive Investors - Finance | 2026-01-07 08:32:00 |
| Merit Financial Group LLC Has $1.05 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN | Merit Financial Group LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 302.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,859 shares of the biopharmaceutical company's stock after purchasing an additional 1,397 shares during the period. Merit Financial Group LLC's | Defense World | 2026-01-07 05:20:55 |
| Seeing Machines CEO on accelerated royalty payment & profit path | Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) CEO Paul McGlone talked with Proactive's Stephen Gunnion about the company’s latest announcement regarding an... | Proactive Investors - Finance | 2026-01-07 04:25:00 |
| REGN vs. ILMN: Which Stock Should Value Investors Buy Now? | Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks? | Zacks Investment Research | 2026-01-06 12:41:18 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. | Zacks Investment Research | 2026-01-06 09:56:08 |
| The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson | Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026. | Zacks Investment Research | 2026-01-06 05:41:09 |
| Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026 | LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026. | Zacks Investment Research | 2026-01-05 08:45:32 |
| Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Ascent Group LLC | Ascent Group LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 56.0% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 581 shares of the biopharmaceutical company's stock after selling 738 shares during the quarter. | Defense World | 2026-01-04 04:06:55 |
| REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? | Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence. | Zacks Investment Research | 2026-01-02 09:40:15 |
| Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again | Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue. | Benzinga | 2026-01-02 08:18:22 |
| Perigon Wealth Management LLC Acquires 985 Shares of Regeneron Pharmaceuticals, Inc. $REGN | Perigon Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 17.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,701 shares of the biopharmaceutical company's stock after buying an additional 985 shares during the period. Perigon Wealth | Defense World | 2025-12-29 06:13:06 |
| Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages | Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-seven ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fifteen have assigned a buy rating and three have | Defense World | 2025-12-29 01:12:56 |
| Global X Japan Co. Ltd. Purchases 904 Shares of Regeneron Pharmaceuticals, Inc. $REGN | Global X Japan Co. Ltd. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 5,650.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 920 shares of the biopharmaceutical company's stock after buying an additional 904 shares during the | Defense World | 2025-12-25 04:48:48 |
| ARS Investment Partners LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN | ARS Investment Partners LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 37.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 28,769 shares of the biopharmaceutical company's stock after buying an additional 7,914 shares during the period. | Defense World | 2025-12-25 03:19:04 |
| Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma | Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo | GlobeNewsWire | 2025-12-23 01:00:00 |
| Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma | Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%) Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized phase 3 study, and inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation Paris and Tarrytown, NY, December 23, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of bronchial asthma in children aged 6 to 11 years with severe or refractory disease whose symptoms are inadequately controlled with existing therapy. | GlobeNewsWire | 2025-12-23 01:00:00 |
| Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique | Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d'asthme bronchique Approbation basée sur le programme mondial de phase 3 chez les enfants démontrant que le Dupixent a considérablement réduit les exacerbations (de 54 % à 65 %) et amélioré la fonction pulmonaire (de 4,68 % à 5,32 %) par rapport au placebo Le Dupixent est le premier et le seul médicament biologique à démontrer une amélioration de la fonction pulmonaire dans ce groupe de jeunes patients dans une étude randomisée de phase 3 et il inhibe l'IL-4 et l'IL-13, deux facteurs clés et centraux de l'inflammation de type 2 Paris et Tarrytown, NY, le 23 décembre 2025. | Globe News Wire | 2025-12-23 01:00:00 |
| Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference | TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days. | GlobeNewsWire | 2025-12-22 16:05:00 |
| Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Osaic Holdings Inc. | Osaic Holdings Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 55.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,068 shares of the biopharmaceutical company's stock after purchasing an additional 6,073 shares during the | Defense World | 2025-12-21 05:18:55 |
| Regeneron: The Turnaround Is Gaining Steam | Regeneron Pharmaceuticals is poised for a turnaround as Eylea's patent cliff fades and new growth drivers emerge. Dupixent and Libtayo are expected to drive robust revenue and margin expansion, with Dupixent collaboration revenues set to increase as the accounting development balance is paid off by Q3 2026. Multiple pipeline catalysts are upcoming in 2026—including Fianlimab, Lynozyfic, and Trevogrumab + Semaglutide—that could accelerate growth and re-rate REGN's valuation. | Seeking Alpha | 2025-12-20 09:30:00 |
| Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal | Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing. | Benzinga | 2025-12-20 01:38:01 |
| Aaron Wealth Advisors LLC Takes $449,000 Position in Regeneron Pharmaceuticals, Inc. $REGN | Aaron Wealth Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 798 shares of the biopharmaceutical company's stock, valued at approximately $449,000. A number of other hedge funds | Defense World | 2025-12-19 03:09:06 |
| Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. | Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on November 18th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account. Representative | Defense World | 2025-12-18 02:06:45 |
| 2 Reasons to Buy Regeneron Stock Like There's No Tomorrow | Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will improve its financial results. | The Motley Fool | 2025-12-13 10:01:00 |
| Regeneron (REGN) Just Flashed Golden Cross Signal: Do You Buy? | From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend. | Zacks Investment Research | 2025-12-12 10:35:20 |
| Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv | The Investment Committee debate the latest Calls of the Day. | CNBC Television | 2025-12-10 13:31:10 |
| Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript | Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript | Seeking Alpha | 2025-12-10 12:42:51 |
| Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial | A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow transplants, preliminary data from a small mid-stage trial suggest. | Reuters | 2025-12-10 12:20:40 |
| Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention? | Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion remaining under its authorized share repurchase program, underscoring its ongoing efforts to create long-term value for its investors. However, I believe the European Commission's approval of Dupixent for the treatment of chronic spontaneous urticaria on November 25 is even more important. | Seeking Alpha | 2025-12-08 14:46:32 |
| California Public Employees Retirement System Sells 158,734 Shares of Regeneron Pharmaceuticals, Inc. $REGN | California Public Employees Retirement System reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 33.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 314,716 shares of the biopharmaceutical company's stock after selling 158,734 shares during the | Defense World | 2025-12-08 04:44:54 |
| Bank of Nova Scotia Purchases 126,689 Shares of Regeneron Pharmaceuticals, Inc. $REGN | Bank of Nova Scotia lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 103.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 249,278 shares of the biopharmaceutical company's stock after buying an additional 126,689 shares during the quarter. Bank | Defense World | 2025-12-08 03:34:57 |
| Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment | All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time | GlobeNewsWire | 2025-12-07 16:30:00 |
| Regeneron's experimental therapy combo effective in untreated cancer patients | Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first part of a late-stage trial. | Reuters | 2025-12-06 09:33:11 |
| Regeneron Pharmaceuticals, Inc. $REGN Position Cut by Groupe la Francaise | Groupe la Francaise lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 45.7% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 4,356 shares of the biopharmaceutical company's stock after selling 3,671 shares during the period. Groupe la Francaise's holdings in Regeneron Pharmaceuticals | Defense World | 2025-12-04 04:42:53 |
| Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Analysts | Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-eight research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, fifteen have given a buy rating and three have | Defense World | 2025-12-04 01:41:03 |
| Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Seeking Alpha | 2025-12-03 14:13:26 |
| Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More | Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wall Street on Tuesday. All of the major indices finished the day higher, with the technology-heavy NASDAQ leading the way, closing up 0.59% at 23,413. The S&P 500 ended the session at 6,829, up 0.25% and the Dow Jones Industrials... Here Are Wednesday's Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy's and More. | 247 Wallst | 2025-12-03 08:15:04 |
| Edgestream Partners L.P. Has $5.45 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN | Edgestream Partners L.P. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 361.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,373 shares of the biopharmaceutical company's stock after acquiring an additional 8,124 shares during the quarter. Edgestream Partners L.P.'s | Defense World | 2025-12-03 04:28:50 |
| Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript | Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript | Seeking Alpha | 2025-12-02 16:53:29 |
| REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD | Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials. | Zacks Investment Research | 2025-12-02 15:25:48 |
| REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? | Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom. | Zacks Investment Research | 2025-12-01 10:51:41 |
| Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) | TARRYTOWN, N.Y. and SOMERVILLE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., today announced a global collaboration to develop and commercialize TSRA-196, Tessera's lead investigational in vivo Gene Writing program for the treatment of alpha-1 antitrypsin deficiency (AATD), an inherited monogenic disease that can affect the lungs, liver, or both organs, and currently impacts approximately 200,000 people in the U.S. and Europe. TSRA-196 is designed to precisely correct the genetic mutation underlying AATD, with the goal of restoring production of functional alpha-1 antitrypsin (AAT) protein through a one-time, durable treatment option for patients. Tessera expects to file an Investigational New Drug and multiple Clinical Trial Applications for TSRA-196 with the U.S. Food and Drug Administration (FDA) by the end of the year. | GlobeNewsWire | 2025-12-01 07:00:00 |
| Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? | Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulation of the medicine that just earned another label expansion. | The Motley Fool | 2025-11-30 23:15:00 |
| Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue? | Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? | Zacks Investment Research | 2025-11-27 12:36:33 |
| SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria | Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU. | Zacks Investment Research | 2025-11-25 11:46:07 |
| Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) | Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflammatory diseases in the EU TARRYTOWN, N.Y. and PARIS, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response to histamine-1 antihistamines (H1AH) and who are naïve to anti-immunoglobulin E (IgE) therapy for CSU. | GlobeNewsWire | 2025-11-25 01:00:00 |
| Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria | Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria | GlobeNewsWire | 2025-11-25 01:00:00 |
| Here are Monday's Top Wall Street Analyst's Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More | The shortened holiday week is here, and the futures are trading higher this morning. | 24/7 Wall Street | 2025-11-24 08:20:45 |
| 1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month | Markets are dipping lower this month, but positive news from the FDA has this biotech stock ripping higher. | Fool - Investing News | 2025-11-24 07:58:40 |
| Bank Julius Baer & Co. Ltd Zurich Sells 1,845 Shares of Regeneron Pharmaceuticals, Inc. $REGN | Bank Julius Baer and Co. Ltd Zurich trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 62.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,092 shares of the biopharmaceutical company's stock after selling 1,845 shares | Defense World | 2025-11-23 04:07:18 |
| AXQ Capital LP Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN | AXQ Capital LP lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 123.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,541 shares of the biopharmaceutical company's stock after purchasing an additional 852 shares during the | Defense World | 2025-11-23 04:07:13 |
| What Moved Markets This Week | Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. | Seeking Alpha | 2025-11-22 06:50:47 |
| Dow Jones Today: Stocks Rise to End Down Week; Fed's Williams Signals Support for December Rate Cut | Stocks advanced to end a week that has seen major equities indexes sell off on concerns about AI spending and valuations of big tech firms, while the price of bitcoin continued to fall. | Investopedia | 2025-11-21 12:01:29 |
| This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead | November's Wall Street obsession hasn't been AI. It's been healthcare. | Investopedia | 2025-11-21 11:05:45 |
| Market Today: Nvidia (NVDA) Whipsaw, Walmart (WMT) Beats; Fed Cut Odds Fade | Guru Stock PicksTweedy Browne has made the following transactions:Reduce in CSCO by 2.83%Sold out in HPKAdd in CROX by 105.33%New position in ALSNStock News AI- | GuruFocus | 2025-11-20 17:34:00 |
| Dow, Nasdaq Up Triple Digits as Nvidia Sparks Tech Rally | The Dow and Nasdaq are sporting triple-digit midday leads after upbeat earnings from Walmart (WMT) and Nvidia (NVDA) | Schaeffers Research | 2025-11-20 12:10:00 |
| Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss | On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly dosing period. | Benzinga | 2025-11-20 11:52:15 |
| REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD | Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion. | Zacks Investment Research | 2025-11-20 10:21:06 |
| First Look: Nvidia beats, Walmart lifts outlook, Gemini 3 debuts | Stock News Nvidia crushes Q3 and guides higher: Nvidia (NVDA) reported record Q3 FY26 revenue of $57.0B (+62% y/y) and guided Q4 sales to $65B, citing âoff th | GuruFocus | 2025-11-20 07:37:00 |
| Bronte Capital Management Pty Ltd. Buys 33,177 Shares of Regeneron Pharmaceuticals, Inc. $REGN | Bronte Capital Management Pty Ltd. lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 21.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 187,870 shares of the biopharmaceutical company's stock after acquiring an additional 33,177 shares during the period. Regeneron Pharmaceuticals accounts | Defense World | 2025-11-20 04:05:06 |
| EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications | First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period | GlobeNewsWire | 2025-11-19 16:10:00 |
| Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation | Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of recurrence or death by 68% (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p | GlobeNewsWire | 2025-11-19 07:00:00 |
| Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript | Regeneron Pharmaceuticals, Inc. ( REGN ) Jefferies London Healthcare Conference 2025 November 17, 2025 10:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Thanks so much, everyone. It's funny. | Seeking Alpha | 2025-11-17 13:07:10 |
| Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript | Regeneron Pharmaceuticals, Inc. ( REGN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 9:20 AM EST Company Participants Mark Hudson - Investor Relations Executive Isreal Lowy - Senior Vice President of Clinical Development Unit Head & Oncology Justin Holko Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Presentation Alexandria Hammond Wolfe Research, LLC Good morning, everybody. My name is Alex Hammond, and I'm the senior biopharma analyst here at Wolfe Research. | Seeking Alpha | 2025-11-17 11:57:12 |
| Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs | Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting | GlobeNewsWire | 2025-11-13 07:00:00 |
| Here Are the Top Growth Healthcare Stocks Every New Investor Should Know | These two healthcare giants have impressive growth potential for different reasons. Eli Lilly is getting a lot of attention for its GLP-1 successes, and another blockbuster could be just around the corner. | The Motley Fool | 2025-11-13 05:15:00 |
| Final Trade: LMAT, REGN, BA, TJX | The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders. | CNBC Television | 2025-11-12 18:20:23 |
| Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | Regeneron Pharmaceuticals, Inc. ( REGN ) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline November 10, 2025 8:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman L. Sirulnik - Senior Vice President of Clinical Development Unit Head & Hematology David Gutstein Conference Call Participants Brian Abrahams - RBC Capital Markets, Research Division Tyler Van Buren - TD Cowen, Research Division David Risinger - Leerink Partners LLC, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research William Pickering - Sanford C. | Seeking Alpha | 2025-11-10 14:31:31 |
| Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review | ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review | GlobeNewsWire | 2025-11-07 08:00:00 |
| Regeneron Announces Investor Conference Presentations | TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: | GlobeNewsWire | 2025-11-03 16:05:00 |
| Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award | Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions | GlobeNewsWire | 2025-10-31 07:00:00 |
| D.A. Davidson & CO. Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN | D.A. Davidson and CO. reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 16.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 609 shares of the biopharmaceutical company's stock after selling 123 shares during the quarter. D.A. | Defense World | 2025-10-31 04:08:54 |
| Pharmaceutical Stocks To Keep An Eye On – October 28th | Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, Pfizer, Incyte, AbbVie, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies whose primary business is researching, developing, manufacturing, and marketing prescription drugs and related therapies. For investors, these stocks | Defense World | 2025-10-30 02:09:35 |
| Top Medical Stocks To Research – October 28th | UnitedHealth Group, Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, and Johnson and Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. "Medical stocks" are publicly traded companies whose primary business is healthcare - including pharmaceuticals, biotechnology, medical-device manufacturers, hospitals and clinics, diagnostics, and related suppliers and service providers. | Defense World | 2025-10-30 02:09:33 |
| Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback | Regeneron Pharmaceuticals, Inc. delivered a strong Q3 earnings beat, driven by Dupixent growth, despite ongoing Eylea sales declines and manufacturing setbacks. REGN's future growth is anchored by Dupixent's expanding indications, a robust late-stage pipeline, and improving Libtayo performance, offsetting Eylea's decline. Management's financial discipline, $7B in manufacturing investments, and share repurchases position REGN for resilience amid regulatory and policy headwinds. | Seeking Alpha | 2025-10-29 13:00:27 |
| Market Starting To Embrace The 'New' Regeneron | Regeneron Pharmaceuticals, Inc. beat Q3 revenue and EPS expectations, and it appears investors are finally embracing the fact the Eylea franchise is no longer a growth product. Eylea franchise faces ongoing revenue declines, but market share losses have stabilized and regulatory issues for Eylea HD should be addressed in 2026. Dupixent collaboration profits with Sanofi are set to accelerate, supporting a return to mid-single-digit revenue growth or better for REGN in 2026. | Seeking Alpha | 2025-10-29 12:01:05 |
| REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase | Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand. | Zacks Investment Research | 2025-10-28 16:05:20 |
| Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript | Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman Marion McCourt - Executive Vice President of Commercial Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Tyler Van Buren - TD Cowen, Research Division Evan Seigerman - BMO Capital Markets Equity Research Brian Abrahams - RBC Capital Markets, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Alexandria Hammond - Wolfe Research, LLC Christopher Schott - JPMorgan Chase & Co, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Presentation Operator Welcome to the Regeneron Pharmaceuticals Third Quarter 2025 Earnings Conference Call. My name is Shannon, and I will be your operator for today's call. | Seeking Alpha | 2025-10-28 13:31:54 |
| Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics | Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. | Zacks Investment Research | 2025-10-28 10:36:09 |
| Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness | Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59. | Benzinga | 2025-10-28 09:13:27 |
| Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates | Regeneron (REGN) came out with quarterly earnings of $11.83 per share, beating the Zacks Consensus Estimate of $9.44 per share. This compares to earnings of $12.46 per share a year ago. | Zacks Investment Research | 2025-10-28 08:41:05 |
| Regeneron beats quarterly estimates on strong demand for Dupixent | Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending its shares up 5.6% premarket. | Reuters | 2025-10-28 07:30:00 |
| Regeneron Reports Third Quarter 2025 Financial and Operating Results | TARRYTOWN, N.Y., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2025 and provided a business update. | GlobeNewsWire | 2025-10-28 06:30:00 |
| Has Regeneron Stock Quietly Become A Value Buy? | Here is why we believe Regeneron Pharmaceuticals (REGN) stock is worthy of consideration as a value investment. It is presently trading nearly 38% lower than its one-year peak, and is also being traded at a price to sales multiple that is beneath the average for the past three years. | Forbes | 2025-10-27 08:35:07 |
| REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? | Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition. | Zacks Investment Research | 2025-10-24 11:02:04 |
| Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning | We purchased several new fund holdings across various sectors. Sempra has been shifting its strategic focus from its highly regulated California operations to its growing presence in Texas. Regeneron in our view has a strong balance sheet and a robust product pipeline. | Seeking Alpha | 2025-10-24 04:30:00 |
| 7 Stocks Taking The Next Step To Be On Offense | Bio-Rad Laboratories was a positive contributor after the company reported steadier earnings than the market expected. PVH also remains our largest share repurchaser for the year after buying a teens percentage of shares outstanding at great prices. Rayonier was an immediate contributor. | Seeking Alpha | 2025-10-23 19:30:00 |
| Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS | Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. | Zacks Investment Research | 2025-10-23 10:16:43 |
| Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline | Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | Zacks Investment Research | 2025-10-21 11:06:22 |
| Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation | Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p | GlobeNewsWire | 2025-10-17 07:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2025-12-31 | 2025-12-31 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-10 | 2025-11-10 | View Filing |
| 13F-HR | 2025-11-07 | 2025-11-07 | View Filing |
| 4 | 2025-10-31 | 2025-10-31 | View Filing |
| 4 | 2025-10-31 | 2025-10-31 | View Filing |
| 10-Q | 2025-10-28 | 2025-10-28 | View Filing |
| 8-K | 2025-10-28 | 2025-10-28 | View Filing |
| 8-K | 2025-10-06 | 2025-10-06 | View Filing |
| SC 13G/A | 2025-08-06 | 2025-08-06 | View Filing |
| 13F-HR | 2025-08-01 | 2025-08-01 | View Filing |
| 10-Q | 2025-08-01 | 2025-08-01 | View Filing |
| 8-K | 2025-08-01 | 2025-08-01 | View Filing |
| 8-K | 2025-06-18 | 2025-06-18 | View Filing |
| SC 13G/A | 2025-06-05 | 2025-06-05 | View Filing |
| 13F-HR | 2025-05-02 | 2025-05-02 | View Filing |
| 10-Q | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-29 | 2025-04-29 | View Filing |
| ARS | 2025-04-29 | 2025-04-29 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| SC 13G/A | 2025-04-22 | 2025-04-22 | View Filing |
| PRE 14A | 2025-04-07 | 2025-04-07 | View Filing |
| SC 13G/A | 2025-02-12 | 2025-02-12 | View Filing |
| 13F-HR | 2025-02-07 | 2025-02-07 | View Filing |
| 10-K | 2025-02-05 | 2025-02-05 | View Filing |
| 8-K | 2025-02-04 | 2025-02-04 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| 4 | 2024-11-12 | 2024-11-12 | View Filing |
| 4 | 2024-11-05 | 2024-11-05 | View Filing |
| S-3ASR | 2024-10-31 | 2024-10-31 | View Filing |
| 10-Q | 2024-10-31 | 2024-10-31 | View Filing |
| 8-K | 2024-10-31 | 2024-10-31 | View Filing |
| 8-K | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-03 | 2024-10-03 | View Filing |
| 4 | 2024-10-03 | 2024-10-03 | View Filing |
| 4 | 2024-09-05 | 2024-09-05 | View Filing |
| 4 | 2024-09-05 | 2024-09-05 | View Filing |
| 4 | 2024-09-05 | 2024-09-05 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-19 | 2024-08-19 | View Filing |
| 4 | 2024-08-19 | 2024-08-19 | View Filing |
| 4 | 2024-08-15 | 2024-08-15 | View Filing |
| 4 | 2024-08-14 | 2024-08-14 | View Filing |
| 4 | 2024-08-12 | 2024-08-12 | View Filing |
| 4 | 2024-08-07 | 2024-08-07 | View Filing |
| 4 | 2024-08-06 | 2024-08-06 | View Filing |
| 4 | 2024-08-05 | 2024-08-05 | View Filing |
| 4 | 2024-08-05 | 2024-08-05 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Adaptive Wave | 24.18% | 1.79 | 3 | 0.02 | 0.07 | 11.19 |
| Larry Williams PercentR Strategy | 22.11% | 1.02 | 241 | 0.04 | 0.15 | 9.12 |
| Super Trend Strategy | 21.00% | 1 | 1085 | 0.02 | 0.09 | 8.02 |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxxx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxx% | xxxx | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxx% | x | xxxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |